Table 2.
Patient Characteristics Grouped by Treatment History
| Total (n = 94) | Naive (n = 25) | Relapser (n = 44) | NR (n = 25) | |
| Age | 56.5 (23–65) | 54 (23–64) | 57.5 (44–65) | 57 (40–65) |
| Sex (M/F) | 52/42 | 13/12 | 27/17 | 12/13 |
| Height (cm) | 163.5 (142–189) | 163 (147–189) | 167.5 (142–177) | 160 (149–174) |
| Weight (kg) | 61 (41–93) | 57 (42–80) | 63.5 (41–93) | 59 (45–77) |
| rs8099917 (TT/GT/GG) | 50/41/3 | 15/9/1 | 33/11/0 | 2/21/2 |
| rs1127354 (CC/CA/AA) | 75/18/1 | 18/6/1 | 34/10/0 | 23/2/0 |
| Viral genotype (1b/others) | 93/1 | 25/0 | 44/0 | 24/1 |
| Core 70 (W/M/ND) | 50/43/1 | 13/12/0 | 28/16/0 | 9/15/1 |
| Core 91 (W/M/ND) | 48/45/1 | 14/11/0 | 23/21/0 | 11/13/1 |
| ISDR (0–1/≥2/ND) | 82/8/4 | 25/0/0 | 38/4/2 | 19/4/2 |
| WBC (/mm3) | 4800 (2800–8100) | 5390 (3000–7500) | 4750 (2800–8100) | 4700 (3040–8000) |
| Plt (×104/mm3) | 18 (9–34) | 20 (15–30) | 16.5 (10–34) | 16 (9–24) |
| Hb (g/dL) | 14.3 (12.3–17) | 14.1 (12.5–16.1) | 14.45 (12.3–17) | 14.4 (12.3–16.6) |
| ALT (IU/L) | 38.5 (12–302) | 35 (12–113) | 39.5 (16–302) | 45 (17–135) |
| γGTP (IU/L) | 36 (11–233) | 31 (11–141) | 34 (14–233) | 49 (21–226) |
| Virus titer (log IU/mL) | 6.7 (5.1–7.7) | 6.7 (5.1–7.4) | 6.7 (5.4–7.6) | 6.7 (5.8–7.7) |
| Days to first ribavirin reduction | 18 (3–168) | 18 (3–52) | 18 (3–168) | 15 (8–52) |
| Duration of telaprevir administration (days) | 85 (29–85) | 85 (29–85) | 85 (32–85) | 85 (35–85) |
| Duration of peg-interferon injection (days) | 162 (22–165) | 163 (22–165) | 162.5 (30–165) | 162 (30–165) |
| Duration of ribavirin administration (days) | 169 (29–169) | 168 (29–169) | 169 (32–169) | 169 (36–169) |
| Effect of therapy (SVR/BT/TR/NR) | 69/4/19/2 | 20/0/5/0 | 41/1/2/0 | 8/3/12/2 |
NOTE. Counts are listed for categorical values and the median and range are reported for continuous variables.